S phingosine 1-phosphate (S1P) is a pleiotropic lipid mediator produced by phosphorylation of sphingosine by sphingosine kinases 1 and 2 in response to a variety of stimuli. 1,2 S1P interacts with 5 related G-protein-coupled receptors termed S1P receptor (S1PR) types 1 to 5, which regulate a wide spectrum of cellular functions, including proliferation and survival, cytoskeletal rearrangements, and cell motility, and exert potent cytoprotective effects. 3, 4 In the vasculature, S1PR1, 2, and 3 were identified on endothelial surface, whereas S1PR2 and S1PR3 are present on smooth muscle cells. Through these receptors S1P is believed to provide essential contribution to the new vessel formation and the maintenance of vascular barrier integrity. 5, 6 In addition, S1P was demonstrated to interfere with proliferation, migration, and activation of lymphocytes and monocytes/macrophages and to regulate their recruitment to sites of inflammation. 7-9 These immunomodulatory activities, which are mediated by S1PR1 and 4 on lymphocytes and S1PR1, 2, 3, and 4 on macrophages, likely account for beneficial effects exerted by S1P and its analogues in animal models of inflammatory diseases, such as ulcerating colitis, viral myocarditis, endotoxin-induced lung injury, or autoimmune encephalomyelitis. [10] [11] [12] [13] Erythrocytes and platelets are major sources of S1P in plasma, where it is associated with a subfraction(s) of high-density lipoprotein (HDL)-a potent plasma-borne antiatherogenic factor. [14] [15] [16] There is substantial evidence Objective-Sphingosine 1-phosphate (S1P) partly accounts for antiatherogenic properties of high-density lipoproteins. We previously demonstrated that FTY720, a synthetic S1P analog targeting all S1P receptors but S1P receptor type 2, inhibits murine atherosclerosis. Here, we addressed the identity of S1P receptor mediating atheroprotective effects of S1P. Approach and Results-Low-density lipoprotein receptor-deficient mice on cholesterol-rich diet were given selective S1P receptor type 1 agonist KRP-203 (3.0 mg/kg per day; 6 and 16 weeks). KRP-203 substantially reduced atherosclerotic lesion formation without affecting plasma lipid concentrations. However, KRP-203 induced lymphopenia, reduced total (CD4 + , CD8 + ) and activated (CD69 + /CD8 + , CD69 + /CD4 + ) T cells in peripheral lymphoid organs, and interfered with lymphocyte function, as evidenced by decreased T-cell proliferation and interleukin-2 and interferon-γ production in activated splenocytes. Cyto-and chemokine (tumor necrosis factor-α, regulated and normal T cell expressed and secreted) levels in plasma and aortas were reduced by KRP-203 administration. Moreover, macrophages from KRP-203-treated mice showed reduced expression of activation marker MCH-II and poly(I:C)-elicited production of tumor necrosis factorα, monocyte chemoattractant protein-1, and interleukin-6. In vitro studies demonstrated that KRP-203 reduced tumor necrosis factor-α, interleukin-6, and interferon-γ-induced protein-10 production; IκB and signal transducer and activator of transcription-1 phosphorylation; and nuclear factor κB and signal transducer and activator of transcription-1 activation in poly(I:C)-, lipopolysaccharide-, or interferon-γ-stimulated bone marrow macrophages, respectively. Conclusions-Present results demonstrate that activation of S1P signaling pathways inhibit atherosclerosis by modulating lymphocyte and macrophage function and suggest that S1P receptor type 1 at least partially mediates antiatherogenic effects of S1P. (Arterioscler Thromb Vasc Biol. 2013;33:1505-1512.) 
suggesting that S1P may directly contribute to atheroprotective effects attributed to HDL. For instance, S1P closely correlates with HDL in a concentration range, in which HDL most effectively protects against atherosclerosis, and decreased HDL-bound S1P levels were noted in patients with coronary artery disease and myocardial infarction. [17] [18] [19] In addition, S1P was found to emulate in vitro several atheroprotective effects attributed to HDL, including inhibition of endothelial apoptosis and enhancing endothelial barrier function, inhibition of expression of adhesion molecules, and stimulation of nitric oxide and prostacyclin generation. 20, 21 However, the evidence underscoring atheroprotective effects of S1P in animal models of atherosclerosis remains controversial. No effects on atherosclerosis or even increased vascular lesion formation have been observed in atherosclerosis-prone mice lacking S1PR3 or S1PR2, respectively. 22, 23 However, FTY720, a synthetic S1P analogue and a high-affinity agonist for S1PR1, 3, 4, and 5, was demonstrated to retard atherosclerosis development in both low-density lipoprotein (LDL) receptordeficient (LDL-R −/− ) and apolipoprotein E-deficient mice fed cholesterol-rich Western diet, suggesting that signaling via ≥1 S1P receptors exerts atheroprotective effects in vivo. 24, 25 To address the identity of S1P receptor with antiatherogenic activity, we here examined the effect of KRP-203, a synthetic and potent S1PR1 agonist, [26] [27] [28] on the development of atherosclerosis in LDL-R −/− mice. Our results confirm that activation of S1P signaling pathways inhibits atherosclerosis chiefly by modulating lymphocyte and macrophage function and suggest that S1PR1 at least partly mediates antiatherogenic effects of S1P.
Materials and Methods
Materials and Methods are available in the online-only Supplement. , a selective S1PR1 agonist structurally related to FTY720, was administered thrice weekly to LDL-R −/− mice at a dose of 3.0 mg/kg per day. Preliminary experiments showed that KRP-203 reduced peripheral lymphocytes by 63.1% 6 h after a single dosage and that this effect persisted after 48 hours ( Figure I in the online-only Data Supplement).
Results

KRP-203 Induces Persistent Lymphopenia in LDL-R −/− Mice
KRP-203 Retards Atherosclerosis and Alters Plaque Cellular Composition
LDL-R −/− mice (16 animals per group) were placed on the atherogenic diet and administered KRP-203 or vehicle as previously described. Six and 10 animals per group were euthanized after 6 and 16 weeks, respectively, and the extent of atherosclerotic lesion development was quantified in the aortic root using serial cross-sections and in thoracic and abdominal aortas by en face analysis. Morphometric quantification of Oil Red O-stained aortic root lesions revealed that KRP-203 treatment for 6 and 16 weeks led to a significant reduction in lesion areas as compared with control mice ( Figure 1A and 1B). Likewise, en face prepared aortas showed significantly reduced percentages of the aortic surface occupied by lesions in mice treated with KRP-203 for 6 weeks and a tendency toward reduction in mice treated for 16 weeks ( Figure 1C 
KRP-203 Fails to Affect Body Weight and Plasma Lipid Profile
Treatment with KRP-203 did not alter mice body weight, plasma lipid concentrations, electrophoretic distribution of lipoprotein fractions, and plasma parameters reflecting liver and renal functions ( Figure III and Table I in the online-only Data Supplement).
KRP-203 Alters Blood Leukocyte Count and Profile
To investigate whether KRP-203 affects lesion formation by modulating peripheral immunity, we first monitored leukocyte abundance and analyzed lymphocyte subpopulations in blood by flow cytometry. As shown in Figure 2A , the absolute amount of lymphocytes was markedly decreased, whereas that of monocytes and neutrophils remained unchanged in LDL-R −/− mice receiving KRP-203. In addition, a drop in T-helper cells (CD4 + ), cytotoxic T cell (CD8 + ), and B cells (CD19 + ) was observed in KRP-203-treated animals ( Figure 2B ).
KRP-203 Affects Lymphocyte Distribution and Suppresses T-Cell Activation
Further experiments demonstrated that altered lymphocyte distribution in blood of KRP-203-treated mice was paralleled by changes in lymphatic organs. As shown in Figure 3A and 3C, KRP-203 administration reduced CD4 + T cells (in spleen and lymph nodes) and CD8 + T cells (in spleen). In addition, spleen and lymph node CD4 + T cells and spleen CD8 + T cells from KRP-203-treated animals showed reduced surface expression of CD69-an early lymphocyte activation marker ( Figure 3B and 3D). In addition to lymphocyte count and subset pattern, we also assessed the influence of KRP-203 on lymphocyte function. To this end, murine splenocytes from control and KRP-203-treated animals were stimulated with concanavalin A (10.0 µg/mL) or phytohaemagglutinin (5.0 µg/ mL), and the proliferation rate of CD4 + T cells was determined by flow cytometry using a carboxyfluorescein succinimidyl ester dilution assay. As shown in Figure 3E , both agonists potently stimulated proliferation of CD4 + T cells from control animals, and this response was significantly inhibited in KRP-203-treated animals. In addition, reduced production of interleukin (IL)-2 and interferon (IFN)-γ, 2 cytokines released from activated CD4 + T cells in response to concanavalin A or phytohaemagglutinin, was noted in splenocytes obtained from KRP-203-treated mice ( Figure 3F ).
KRP-203 Inhibits Macrophage and Dendritic Cell Activation in LDL-R −/− Mice
As T-cell activation is controlled by antigen-presenting cells, we next examined the effect of KRP-203 on the function of macrophages and dendritic cells. To this aim, surface expression of costimulatory molecule major histocompatibilty complex class II defining the subpopulation of activated antigen-presenting cells was examined in peritoneal leukocytes and splenocytes positive for F4/80 + (a macrophage marker) or CD11c + (a dendritic cell marker). As shown in Figure 4A , both peritoneal and spleen cells obtained from KRP-203treated animals presented with decreased expression of major histocompatibilty complex II on F4/80 + and CD11c + cells. Because macrophage and dendritic cell activation is associated with enhanced secretion of several inflammatory mediators, we next tested for changes in cytokine and chemokine production in peritoneal leukocytes brought about by KRP-203 administration. As shown in Figure 4B , concentrations of tumor necrosis factor (TNF)-α monocyte chemoattractant protein-1, and IL-6, cyto/chemokines produced predominantly by macrophages, were similar in peritoneal cell supernatants from KRP-203-treated and control LDL-R −/− mice in a basal state. However, after stimulation with poly(I:C), a Toll-like receptor 3 agonist, peritoneal cells obtained from KRP-203treated animals produced significantly less TNFα, monocyte chemoattractant protein-1, and IL-6. The modification of cytokine production profile evoked in peritoneal cells by KRP-203 administration was paralleled by changes in cytokine levels is plasma and aortas. As shown in Figure 4C , treatment of LDL-R −/− mice with KRP-203 markedly reduced plasma concentrations of TNFα and regulated and normal T cell expressed and secreted (RANTES)-a chemokine secreted by both macrophages and lymphocytes. Figure 4D demonstrates that mRNA expression levels of TNFα and RANTES were reduced in atherosclerotically changed aortas from KRP-203treated mice.
KRP-203 Inhibits Macrophage Activation In Vitro
In the next step, we assessed direct effects of KRP-203 on macrophage activation under in vitro conditions. To this aim, murine bone marrow-derived macrophages were exposed to various concentrations of KRP-203 for 24 hours and stimulated with poly(I:C), lipopolysaccharide (LPS; Toll-like receptor 4 agonist), or IFNγ for further 24 hours in the presence of the compound. As shown in Figure 5A , production of proinflammatory cytokines, TNFα and IL-6, in response to poly(I:C) or LPS and interferon-γ-induced protein-10 in response to IFNγ was inhibited by KRP-203. The reduced response to proinflammatory stimuli as a consequence of direct inhibitory action of KRP-203 was further reflected at the transcriptional level by impaired upregulation of poly(I:C)-or LPS-induced nuclear factor κB (NFκB) activation or IFNγ-induced signal transducer and activator of transcription (STAT)-1 activation in bone marrow-derived macrophages pretreated for 24 hours with KRP-203 and transiently transfected with reporter plasmids containing either NFκB-or STAT1-responsive promoters ( Figure 5B ). At pretranscriptional level, the poly(I:C)or LPS-induced phosphorylation of IκB, a component of the NFκB complex, and IFNγ-induced phosphorylation of STAT1, which both precede the initiation of transcription by NFκB or STAT1, respectively, were reduced in bone marrowderived macrophages pretreated for 24 hours with KRP-203 ( Figure 5C ).
KRP-203 Inhibits Endothelial Activation In Vitro
Because reduction of the lesion macrophage content in KRP-203-treated animals might be a consequence of reduced transendothelial migration, we also assessed the effect of KRP-203 on in vitro monocyte adhesion and endothelial barrier functions. We found that pretreatment of bEnd.5 murine endothelial cells with KRP-203 reduced TNFα-induced vascular cell adhesion protein-1 expression and static adhesion of U937 monocytes ( Figure IVA and IVB in the online-only Data Supplement). In addition, endothelial permeability to FITC-dextran and U937 monocytes was attenuated in bEnd.5 cells pretreated with KRP-203 ( Figure IVC 
Discussion
There is a substantial body of evidence documenting that antiatherogenic effects of HDL can be at least partly attributed to its S1P content, but only few studies assessed the role of S1P in the atherosclerotic lesion development in animal models. We and others have previously shown that the S1P analogue FTY720 attenuates the development of atherosclerosis in LDL-R −/− and apolipoprotein E-deficient mice. 24, 25 However, the latter compound does not allow discriminating between the roles of individual S1P receptors, as it engages all receptor subtypes except S1P2. Therefore, to narrow down the identity of S1P receptor specifically mediating atheroprotective effects in mice, we used KRP-203-a synthetic compound that shares some structural characteristics with FTY720, but binds with high affinity only to S1PR1. [26] [27] [28] In rodents, KRP-203 has been effective in preventing transplant rejection. 29 In addition, it ameliorated autoimmune myocarditis in rats, as well as inflammatory liver disease and colitis in mice. 26, 30, 31 In the present study, we demonstrate that administration of KRP-203 to cholesterol-rich diet-fed LDL-R −/− mice inhibits the development of atherosclerotic lesions. This observation reinforces the notion that S1P contributes to the antiatherogenic potential of HDL and points to S1PR1 as a receptor at least partially mediating atheroprotective effects of S1P.
Because KRP-203 failed to affect plasma lipid levels, it seems unlikely that its capacity to protect against atherosclerosis is linked to alterations of lipid metabolism. Rather, it could be related to the ability of this compound to interfere with recruitment and function of inflammatory cells relevant to the pathogenesis of atherosclerosis, such as T cells or macrophages. Similar to FTY720, KRP-203 promotes lymphopenia in peripheral blood, [29] [30] [31] and this effect has been recapitulated in the present study in hyperlipidemic LDL-R −/− mice. It is conceivable that reducing the number of CD4 + and CD8 + T cell in the periphery per se helps to limit lymphocyte infiltration into atherosclerotically changed arterial wall and thereby to inhibit atherosclerosis development. Unlike FTY720, administration of KRP-203 also decreased number of macrophages within atherosclerotic lesions. Previous studies documented that both KRP-203 and other structurally unrelated S1PR1 agonists (SEW2871, AUY954) were effective in reducing the recruitment of both lymphocytes and monocytes to inflamed areas of heart, kidney, liver, and peripheral nerves and attributed these effects to the direct modulation of endothelial cells. [29] [30] [31] [32] [33] [34] The present study extends these findings by showing that treatment with KRP-203 reduces monocyte adhesion to endothelial cells and improves endothelial barrier function. It cannot, therefore, be excluded that KRP-203 reduces the number of inflammatory cells in atherosclerotic lesions by preventing leukocyte migration across the endothelial barrier. This contention is further supported by the observation that the efficacy of KRP-203 with respect to lesion formation decreases over time, which suggests that this compound preferentially interferes with early mechanisms contributing to lesion formation, such as monocyte entry into arterial wall.
Both T cells and macrophages are highly involved in the development of atherosclerosis. These cells are abundantly present throughout human and murine plaques and their interaction is required for the development of fully fledged inflammation within arterial wall. Macrophages in the plaque, which in major part exhibit proinflammatory activation phenotype (M1) and secrete cyto-and chemokines, including TNFα and RANTES, are believed to drive Th1 lymphocyte polarization. 35, 36 Conversely, IFNγ-producing Th1 cells that dominate during atherogenesis promote M1 phenotype in macrophages, and inactivation of the T-bet transcription factor controlling Th1 development protects against atherosclerosis. [37] [38] [39] The present study provides 2 pieces of evidence suggesting that KRP-203 may interfere with reciprocal macrophage-lymphocyte activation and thereby counteract the development of atherosclerosis. First, administration of KRP-203 to LDL-R −/− mice suppressed T-cell activity as evidenced by the decreased expression of CD69, an early activation marker, on the cell surface of T cells recovered from peripheral lymphatic organs. The latter effect was accompanied by the reduced T-cell proliferation and the production of Th1 cytokines, including IFNγ. In addition, important mediators of Th1 polarization, such as RANTES, 40 were decreased in KRP-203-treated animals. Second, the reduced surface expression of costimulatory molecule major histocompatibilty complex II, which serves as a sensitive marker of macrophage activation, was observed in macrophages obtained from mice receiving KRP-203. Moreover, continuous treatment with this compound was associated with decreased production of proinflammatory cytokines, such as TNFα, monocyte chemoattractant protein-1, and IL-6 by peritoneal macrophages exposed ex vivo to agonists of Toll-like receptors, which are known to drive M1 polarization within atheromas. 41 Reduced proinflammatory cytokine production and activation of transcription factors, NFκB and STAT1, in response to poly(I:C), LPS, or IFNγ, were also observed in vitro in bone marrow macrophages exposed to KRP-203. Collectively, our results suggest that the increased signaling via S1PR1 suppresses proinflammatory polarization both in T cells and in macrophages. Because hyperactivation of M1-Th1 axis is critical to the development of atherosclerosis and elimination of its cellular (CD4 + T cells, CD8 + T cells) or humoral (IFNγ, RANTES) components abrogates atherosclerotic lesion formation in mice, [42] [43] [44] [45] it is reasonable to assume that atherprotective effects of KRP-203 in hyperlipidemic LDL-R −/− mice are at least partly related to the negative modulation of macrophage and T-cell function.
No firm conclusion can be drawn on the basis of the present results as to which mechanism underlies the inhibitory effects exerted by KRP-203 on inflammatory cells. Studies using FTY720 in lymphocytes showed that prolonged incubation with this compound facilitates internalization and degradation of S1PR1 resulting in cells with lower responsiveness to S1P. 46 Although it is currently unknown whether KRP-203 also desensitizes S1P receptors, our data demonstrating reduced cytokine production and transcription factor activation in bone marrow macrophages pretreated with KRP-203 suggest that at least in macrophages this compound behaves as the direct S1PR1 agonist. This contention is concordant with previous studies, which demonstrated that S1PR1 activation directly dampens macrophage reactivity to proinflammatory stimuli. For instance, CYM5442 and SEW2871, 2 structurally distinct and selective S1PR1 agonists, were reported to attenuate production of proinflammatory cytokines in response to LPS. [47] [48] [49] Interestingly, SEW2871 was also found to reduce CD69 expression and IFNγ production in CD4 + T cells obtained from nonobese diabetic mice indicating that S1PR1 agonists may directly interfere with lymphocyte activation in vivo. 50 Current knowledge on the role played by S1P receptor subtypes in atherosclerosis is incomplete. Both pharmacological blockade and genetic elimination of S1PR2 in macrophages attenuated atherosclerosis and reduced macrophage count in plaques suggesting that this receptor exerts proatherogenic effects in mice. 22 Although murine S1PR3 deficiency did not alter atherosclerotic lesion size, it nevertheless modulated neointima formation arguing for protective role of S1PR3 in the arterial injury response. 23 To our knowledge, the involvement of S1PR1 in the initiation and progression of atherosclerosis has not been addressed to date in the animal model of this disease. There are, however, several hints from in vitro studies pointing to atheroprotective effects of S1PR1 signaling. For instance, important antiatherogenic effects of HDL, including the stimulation of endothelial NO production, the inhibition of adhesion molecule expression, and the enhancement of endothelial barrier as well as the inhibition of Toll-like receptor signaling in macrophages, were abrogated after reduction of S1PR1 expression with siRNA or in the presence of pharmacological S1PR1 antagonists. [51] [52] [53] In addition, statins were reported to enhance S1PR1 expression in endothelial cells and thereby to potentiate NO production in response to HDL. 54 The present study is the first to show that activation of S1PR1 signaling in the murine model of atherosclerosis reduces atherosclerotic plaque formation, favorably affects plaque cellularity, improves endothelial function, and concomitantly inhibits activation of macrophages and lymphocytes, thereby modulating general inflammatory response. These results together with previous studies using FTY720 suggest that S1PR1 agonists might be advantageous for treatment of early atherosclerosis. Unfortunately, most of S1PR1 agonists persistently decrease peripheral lymphocyte count, which obviously limits their use for treatment of chronic conditions. In this respect, however, it is worth noticing that SEW2871-S1PR1 agonist, which does not promote S1PR1 degradation or behave like functional S1PR1 antagonist-maintains protective effects in animals models of inflammatory diseases, such as renal ischemia-reperfusion injury or diabetic nephropathy independent of lymphocytes. 34, 47, 55 Clearly, new S1PR agonists with more favorable pharmacological properties have to be developed before the antiatherogenic potential of these compounds can be fully explored.
In conclusion, the present results demonstrate that activation of S1P signaling pathways inhibit atherosclerosis by modulating lymphocyte and macrophage function and improving endothelial barrier. It is suggested that atheroprotective effects of S1P are chiefly mediated by S1PR1, although the involvement of other S1P receptors cannot be excluded.
